|
JP2007515429A
(ja)
*
|
2003-12-19 |
2007-06-14 |
エリクシアー ファーマシューティカルズ， インコーポレイテッド |
障害を治療する方法
|
|
WO2005090320A2
(en)
*
|
2004-03-12 |
2005-09-29 |
Wyeth |
Triazole derivatives and method of using the same to treat hiv infections
|
|
WO2006026619A2
(en)
*
|
2004-08-30 |
2006-03-09 |
Government Of The United States Of America As Represented By The Secretary Department Of Health And Human Services |
Inhibition of viruses using rnase h inhibitors
|
|
US7649098B2
(en)
*
|
2006-02-24 |
2010-01-19 |
Lexicon Pharmaceuticals, Inc. |
Imidazole-based compounds, compositions comprising them and methods of their use
|
|
US8227603B2
(en)
*
|
2006-08-01 |
2012-07-24 |
Cytokinetics, Inc. |
Modulating skeletal muscle
|
|
PL2069352T3
(pl)
*
|
2006-08-02 |
2014-03-31 |
Cytokinetics Inc |
Określone cząstki chemiczne, kompozycje i sposoby
|
|
US8299248B2
(en)
*
|
2006-08-02 |
2012-10-30 |
Cytokinetics, Incorporated |
Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use
|
|
AU2007319786A1
(en)
*
|
2006-11-15 |
2008-05-22 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as protein kinase inhibitors
|
|
EP2139478A4
(en)
*
|
2007-03-30 |
2010-05-05 |
Cytokinetics Inc |
CHEMICAL ENTITIES, COMPOSITIONS AND METHODS
|
|
TW200920355A
(en)
*
|
2007-09-06 |
2009-05-16 |
Lexicon Pharmaceuticals Inc |
Compositions and methods for treating immunological and inflammatory diseases and disorders
|
|
KR101614723B1
(ko)
|
2008-01-11 |
2016-04-22 |
알바니 몰레큘라 리써치, 인크. |
Ｍｃｈ 길항물질로서 (1-아지논)-치환된 피리도인돌
|
|
US7998976B2
(en)
*
|
2008-02-04 |
2011-08-16 |
Cytokinetics, Inc. |
Certain chemical entities, compositions and methods
|
|
EP2244711A4
(en)
*
|
2008-02-04 |
2011-08-24 |
Cytokinetics Inc |
CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS
|
|
JP2012513481A
(ja)
*
|
2008-12-23 |
2012-06-14 |
プレジデント アンド フェロウズ オブ ハーバード カレッジ |
ネクロトーシスの小分子阻害剤
|
|
US8618299B2
(en)
*
|
2009-07-01 |
2013-12-31 |
Albany Molecular Research, Inc. |
Azinone-substituted azapolycycle MCH-1 antagonists, methods of making, and use thereof
|
|
JP2012532144A
(ja)
*
|
2009-07-01 |
2012-12-13 |
アルバニー モレキュラー リサーチ， インコーポレイテッド |
アジノン置換アゼピノ［ｂ］インドールおよびピリド−ピロロ−アゼピンｍｃｈ−１拮抗薬、ならびにその作製方法および使用
|
|
WO2011003007A1
(en)
*
|
2009-07-01 |
2011-01-06 |
Albany Molecular Research, Inc. |
Azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine mch-1 antagonists, methods of making, and use thereof
|
|
US9073925B2
(en)
*
|
2009-07-01 |
2015-07-07 |
Albany Molecular Research, Inc. |
Azinone-substituted azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof
|
|
AU2010270797B2
(en)
|
2009-07-08 |
2015-03-19 |
Dermira (Canada), Inc. |
TOFA analogs useful in treating dermatological disorders or conditions
|
|
SG10201510665WA
(en)
|
2009-12-04 |
2016-01-28 |
Sunovion Pharmaceuticals Inc |
Multicycle Compounds And Pharmaceutical Compositions Useful For The Treatment Of Neurological Disorders
|
|
AR082453A1
(es)
|
2010-04-21 |
2012-12-12 |
Novartis Ag |
Compuestos de furopiridina, composiciones farmaceuticas que los contienen y usos de los mismos
|
|
WO2012061342A2
(en)
|
2010-11-01 |
2012-05-10 |
Arqule, Inc. |
Substituted benzo-imidazo-pyrido-diazepine compounds
|
|
US8697700B2
(en)
|
2010-12-21 |
2014-04-15 |
Albany Molecular Research, Inc. |
Piperazinone-substituted tetrahydro-carboline MCH-1 antagonists, methods of making, and uses thereof
|
|
US8993765B2
(en)
|
2010-12-21 |
2015-03-31 |
Albany Molecular Research, Inc. |
Tetrahydro-azacarboline MCH-1 antagonists, methods of making, and uses thereof
|
|
US8754114B2
(en)
|
2010-12-22 |
2014-06-17 |
Incyte Corporation |
Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
|
|
BR112014000742A2
(pt)
|
2011-07-13 |
2016-08-23 |
Andrew A Wolff |
terapia de combinação de als
|
|
RS58514B1
(sr)
|
2012-06-13 |
2019-04-30 |
Incyte Holdings Corp |
Supstituisana triciklična jedinjenja kao inhibitori fgfr
|
|
US9388185B2
(en)
|
2012-08-10 |
2016-07-12 |
Incyte Holdings Corporation |
Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
|
|
US9266892B2
(en)
|
2012-12-19 |
2016-02-23 |
Incyte Holdings Corporation |
Fused pyrazoles as FGFR inhibitors
|
|
US20160024098A1
(en)
|
2013-03-15 |
2016-01-28 |
President And Fellows Of Harvard College |
Hybrid necroptosis inhibitors
|
|
PH12015502383B1
(en)
|
2013-04-19 |
2023-02-03 |
Incyte Holdings Corp |
Bicyclic heterocycles as fgfr inhibitors
|
|
US10851105B2
(en)
|
2014-10-22 |
2020-12-01 |
Incyte Corporation |
Bicyclic heterocycles as FGFR4 inhibitors
|
|
MA41551A
(fr)
|
2015-02-20 |
2017-12-26 |
Incyte Corp |
Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
|
|
TWI712601B
(zh)
|
2015-02-20 |
2020-12-11 |
美商英塞特公司 |
作為fgfr抑制劑之雙環雜環
|
|
US9580423B2
(en)
|
2015-02-20 |
2017-02-28 |
Incyte Corporation |
Bicyclic heterocycles as FGFR4 inhibitors
|
|
AU2016330895A1
(en)
*
|
2015-09-30 |
2018-05-10 |
Gilead Sciences, Inc. |
Compounds and combinations for the treatment of HIV
|
|
MA45795A
(fr)
|
2016-07-29 |
2019-06-05 |
Sunovion Pharmaceuticals Inc |
Composés et compositions, et utilisations associées
|
|
PT3494119T
(pt)
|
2016-07-29 |
2024-12-10 |
Pgi Drug Discovery Llc |
Compostos e composições e seus usos
|
|
MX390141B
(es)
|
2017-02-16 |
2025-03-20 |
Sunovion Pharmaceuticals Inc |
Metodos para tratar esquizofrenia
|
|
AR111960A1
(es)
|
2017-05-26 |
2019-09-04 |
Incyte Corp |
Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
|
|
CA3070993C
(en)
|
2017-08-02 |
2025-05-20 |
Sunovion Pharmaceuticals Inc. |
ISOCHROMANE COMPOUNDS AND THEIR USES
|
|
UA130249C2
(uk)
|
2018-02-16 |
2025-12-31 |
Сумітомо Фарма Америка, Інк. |
Солі, кристалічні форми і способи їх отримання
|
|
HRP20241288T1
(hr)
|
2018-05-04 |
2024-12-06 |
Incyte Corporation |
Čvrsti oblici fgfr inhibitora i postupci za njihovu proizvodnju
|
|
AU2019262579B2
(en)
|
2018-05-04 |
2024-09-12 |
Incyte Corporation |
Salts of an FGFR inhibitor
|
|
US11628162B2
(en)
|
2019-03-08 |
2023-04-18 |
Incyte Corporation |
Methods of treating cancer with an FGFR inhibitor
|
|
EP3938045A1
(en)
|
2019-03-14 |
2022-01-19 |
Sunovion Pharmaceuticals Inc. |
Salts of a isochromanyl compound and crystalline forms, processes for preparing, therapeutic uses, and pharmaceutical compositions thereof
|
|
US11591329B2
(en)
|
2019-07-09 |
2023-02-28 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
WO2021067374A1
(en)
|
2019-10-01 |
2021-04-08 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
CA3157361A1
(en)
|
2019-10-14 |
2021-04-22 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
WO2021076728A1
(en)
|
2019-10-16 |
2021-04-22 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
CA3163875A1
(en)
|
2019-12-04 |
2021-06-10 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
JP7832891B2
(ja)
|
2019-12-04 |
2026-03-18 |
インサイト・コーポレイション |
Ｆｇｆｒ阻害剤の誘導体
|
|
US12012409B2
(en)
|
2020-01-15 |
2024-06-18 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
CA3180115A1
(en)
|
2020-04-14 |
2021-10-21 |
Sunovion Pharmaceuticals Inc. |
(s)-(4,5-dihydro-7h-thieno[2,3-c]pyran-7-yl)-n-methylmethanamine for treating neurological and psychiatric disorders
|
|
WO2021257863A1
(en)
|
2020-06-19 |
2021-12-23 |
Incyte Corporation |
Pyrrolotriazine compounds as jak2 v617f inhibitors
|
|
US11691971B2
(en)
|
2020-06-19 |
2023-07-04 |
Incyte Corporation |
Naphthyridinone compounds as JAK2 V617F inhibitors
|
|
US11767323B2
(en)
|
2020-07-02 |
2023-09-26 |
Incyte Corporation |
Tricyclic pyridone compounds as JAK2 V617F inhibitors
|
|
CR20230057A
(es)
|
2020-07-02 |
2023-08-15 |
Incyte Corp |
Compuestos tríciclicos de urea como inhibidores de jak2 v617f
|
|
US11661422B2
(en)
|
2020-08-27 |
2023-05-30 |
Incyte Corporation |
Tricyclic urea compounds as JAK2 V617F inhibitors
|
|
US11919908B2
(en)
|
2020-12-21 |
2024-03-05 |
Incyte Corporation |
Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors
|
|
AR125273A1
(es)
|
2021-02-25 |
2023-07-05 |
Incyte Corp |
Lactamas espirocíclicas como inhibidores de jak2 v617f
|
|
WO2022221170A1
(en)
|
2021-04-12 |
2022-10-20 |
Incyte Corporation |
Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
|
|
US11939331B2
(en)
|
2021-06-09 |
2024-03-26 |
Incyte Corporation |
Tricyclic heterocycles as FGFR inhibitors
|
|
CA3220155A1
(en)
|
2021-06-09 |
2022-12-15 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
AU2023235313A1
(en)
|
2022-03-17 |
2024-10-03 |
Incyte Corporation |
Tricyclic urea compounds as jak2 v617f inhibitors
|
|
CN116919949B
(zh)
*
|
2023-08-31 |
2024-03-22 |
中国医学科学院医药生物技术研究所 |
2-氨基-5-苯基噻吩-3-羧酸酰胺在制备抗新型冠状病毒药物中的应用
|